The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.
Obese Male and Female adults with BMI 32-42 kg/m²
Elevated blood test for hsCRP consistent with chronic systemic inflammation
At least one cardiovascular risk factor or metabolic syndrome feature
Stable background therapies and willing to maintain stable diet/exercise habits during the study
Type 1 diabetes,
Uncontrolled Type 2 diabetes,
Uncontrolled hypertension and /or hyperlipidemia
Recent weight change of 5% or more,